ISPN Abstract Submission Guidelines

2019 Annual Conference
May 29-June 1, 2019
Charlotte Marriott City Center Hotel
Charlotte, NC USA

Critical Conversations with Psychiatric Nurses:
Preparing for the Next Decade

General Abstract Submission Deadline is
Thursday, November 15, 2018
12:00 midnight PST

Student Posters: Submission Deadline is
Thursday November 15, 2018
12:00 midnight PST

Please develop abstract submissions around the conference theme and suggested content listed below.

Suggested Content

The International Society of Psychiatric-Mental Health Nurses (ISPN) is offering a program of presentations and posters that addresses cutting-edge issues related to innovative clinical practice, education, and research, and diversity in the psychiatric-mental health field.

Annual Conference Objectives

At the end of this conference, the participant should be able to:

a. Evaluate the academic and continuing education issues that continue to emerge in the 21st century.
b. Examine mental health care issues through scholarly inquiry.
c. Synthesize new trends in Evidence-Based Practice to enhance mental health care delivery.
d. Identify innovative leadership strategies to advance the profession.
e. Identify the role of advanced practice nursing in providing psychopharmacological care.
f. Examine a psychopharmacological issue related to a specific population.
Types of Submissions

Annual Conference:
Abstracts will be sorted into five (5) categories:

• Research
• Evidence-Based Practice
• Education/Teaching Pedagogy
• Leadership Development
• Psychopharmacology

PHARMACOLOGY CONTENT
Pharmacology continuing education (CE) is designed to enhance the learner’s ability to prescribe and/or monitor patients on pharmacotherapy. It includes topics such as pharmacokinetics and clinical applications of drugs. Pharmacology credit must be supported by an activity’s objective(s) and detailed content. Incidental mention of drugs or a pharmacological treatment does not qualify for pharmacology credit.

For all categories, you will be asked to indicate how many estimated minutes of your CE activity will focus on pharmacology, on a scale of 0-180 minutes.

Presentation Content/Format

1. **Concurrent Sessions (60 minutes)** are focused on the presentation of a specific topic (e.g. research, clinical, administrative, education) that can be presented in a limited amount of time. Preference will be given to presentations that demonstrate active engagement of participants.
   a. Research presentations – preference will be given to those presentations focusing on outcomes and implications to PMH practice.
   b. Evidence-based practice presentations – preference will be given to those presentations that are case-based learning
   c. Education presentations – preference will be given to those presentations with direct correlation to teaching
   d. Leadership presentations – preference will be given to those presentations offering methodologies to grow personal and professional leadership skills.
   e. Psychopharmacology – preference will be given to those presentations focusing on a psychopharmacological issue related to a specific population.

2. **Symposium (3 hours)** is a meeting in which a group of people shares a collection of essays or papers on a particular subject. Preference will be given to abstracts providing an outline of content to be covered and demonstrating interactive teaching methods.

3. **Workshop (90 minutes)** is a meeting in which a group of people engages in intense discussion with facilitated activities and exercises on a particular subject. A workshop is generally more interactive, and participants have an opportunity to practice hands-on skill building. Preference will be given to abstracts that clearly meet the description above.

4. **Poster Presentation**: See following description.

Poster Presentation
A poster presentation is an exhibit of a topic that provides a forum for one-to-one discussion with colleagues. Research in progress may be submitted as a poster before completion. Poster presenters will be provided a 4’ high by 8’ wide tack board to display their presentation. No audio-visual equipment may be used with the poster presentations.

Included in the presentation space must be a prepared heading for the top of the poster that includes the title, and authors with lettering at least 1.5 inches high. A copy of the abstract should be posted, as well. Illustrations and text should be readable from a distance of six feet. The poster should be displayed in an organized fashion so that it is self-explanatory.

Poster presentations will be sorted into 3 categories:

1. **Research** as purely science and generation of new knowledge.
2. **Evidence-Based Practice** (includes evaluation or quality improvement projects of clinical care/practices or education). Issue of literature review will be decided based on the foci-(Research aimed to generate new knowledge OR Evidence-Based Practice if aimed to inform evaluation or quality improvement in clinical practice or education.
3. **Student** (Research or Evidence-Based Practice)

**Method of Submission**

ISPN uses an online submission process. The online Abstract Submission process is divided into three information areas:

- Information related to the Lead Author
- Information related to any contributing Authors
- Information related to the Abstract, audience, and presentation preferences

1. All abstract submission field names displayed in Red are **required fields and must be completed**. You will have the opportunity to modify your submission at any time prior to the submission deadline.
2. All Abstract Submission information is posted to a database for a “blind review” by the ISPN Review Committee.
3. The first Author entered will be listed as the Lead Author. At any time prior to the Abstract Submission deadline, the current Lead Author may select another Author to assume that role.
4. After the first online Abstract Submission session for a new Abstract, a UserID and Password will be sent to the Lead Author in a confirmation email.
5. The Lead Author should retain the confirmation email for their records and to enable them to make future additions or changes to their information.
6. Changes can be made by the Lead Author to any of the information submitted and additional information can be added at any subsequent time up to the submission deadline date. Changes can be made to your abstract submission through **November 15, 2018, at 12:00 midnight PST**.
7. A preview of the current status of all Abstract Submission information can be viewed or printed by the Lead Author at anytime up to the submission deadline date. It is the lead author’s responsibility to log in to the abstract submission website prior to the submission deadline date to view a preview of your abstract and confirm that it is complete and accurate.
8. The lead author must communicate all presentation information to any co-authors that will be presenting with them at the Annual Conference.
9. **Publications Agreement**: You will be required to select whether or not you give permission for duplication of this abstract, along with any accompanying presentation handouts, for inclusion in the conference proceedings and available for attendees to view on the ispn-psych.org website, and for their storage in the ISPN archives.
Abstract Title, Content, and Word Count

Type your abstract text directly into the "Abstract Title" and "Abstract Content" boxes or copy and paste text FROM A TEXT EDITOR such as Notepad (Windows) or BBEdit (MAC). Please DO NOT copy and paste from a Microsoft Word or any other word processor document UNLESS IT HAS ALREADY BEEN SAVED IN TEXT (.txt) FORMAT. This will enable us to add your preferred formatting to your abstract submission.

Special formatting buttons have been provided on the webpage (Bold, Italics, numbered list and bullets). Use ONLY the special formatting buttons on the webpage to format text in the “Abstract Content” field. Other fields do not require formatting as they will not become part of the final printed abstract.

Abstract Title (maximum 50 words) should not contain identifying information such as author, organization or region. Please use “Title” case. (e.g. My Abstract Title.)

Abstract Content (maximum 350 words) should not contain identifying information such as author, institution, or region.

Review Process
The Abstract Review Committee determines an overall score after conducting a blind review based on the following criteria:

• Significance and innovative content
• Learning objectives related to abstract content
• Relevance and timeliness of content to psychiatric nursing practice
• Overall quality and program balance

Notification
Decisions will be made by mid-January and notification will be sent by email immediately following. Lead authors may contact the ISPN Office if they have not received notification by January 20, 2019. To protect the integrity of the review process, ISPN cannot release status information to co-authors or other third parties.

Decisions made by the Program Committee are final. Only the Lead Author will receive notification of abstract status.

Acceptance
All presenters are required to submit additional biographical and educational information upon acceptance. Lead authors are responsible for acquiring the above information from supporting authors. In support of ISPN, all speakers are required to register for the Conference.

Speaker Agreement
By returning the requested initial documents, speakers who are not submitting their papers for publication agree that abstract and conference presentation handouts will be available to be published in the conference materials on the ISPN website. Deadline for the return of initial materials is February 22, 2019. After this date, ISPN will not include your abstract in the program.

Those planning to submit their papers for publication should not include a slide of findings for publication in the conference presentation handouts on the ISPN website. The speaker should instead share the findings orally at the conference and can include on the slide the following wording, “This paper is being submitted for publication and, therefore, written findings will be included in that medium.”